申请人:[en]MONTE ROSA THERAPEUTICS, INC.
公开号:WO2024151547A1
公开(公告)日:2024-07-18
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrades Proto-oncogene VAV 1 protein (VAV1). The chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having an inflammatory or autoimmune disorder.